| Entry |
| ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Name | Binimetinib (JAN/USAN); Mektovi (TN) | ||||||||
| Product | MEKTOVI (Array BioPharma) | ||||||||
| Formula | C17H15BrF2N4O3 | ||||||||
| Exact mass | 440.0296 | ||||||||
| Mol weight | 441.2268 | ||||||||
| Structure |  | ||||||||
| Simcomp | |||||||||
| Class | Antineoplastic DG03137 MEK inhibitor | ||||||||
| Remark |
| ||||||||
| Efficacy | Antineoplastic, Mitogen-activated extracellular signal-regulated kinase (MEK) inhibitor | ||||||||
| Disease | Melanoma (BRAF mutation positive) [DS:H00038] | ||||||||
| Target | MAP2K1 (MEK1) [HSA:5604] [KO:K04368] MAP2K2 (MEK2) [HSA:5605] [KO:K04369] | ||||||||
| Network |
| ||||||||
| Pathway |
| ||||||||
| Interaction | |||||||||
| Brite | Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS L01 ANTINEOPLASTIC AGENTS L01E PROTEIN KINASE INHIBITORS L01EE Mitogen-activated protein kinase (MEK) inhibitors L01EE03 Binimetinib D10604 Binimetinib (JAN/USAN) <JP/US> USP drug classification [BR:br08302] Antineoplastics Molecular Target Inhibitors Binimetinib D10604 Binimetinib (JAN/USAN) Therapeutic category of drugs in Japan [BR:br08301] 4 Agents affecting cellular function 42 Antineoplastics 429 Miscellaneous 4291 Other Antitumors D10604 Binimetinib (JAN/USAN) Drug groups [BR:br08330] Antineoplastic DG03137 MEK inhibitor D10604 Binimetinib Drug classes [BR:br08332] Antineoplastic DG03137 MEK inhibitor D10604 Binimetinib Target-based classification of drugs [BR:br08310] Protein kinases Serine/threonine kinases STE group MAP2K1 (MEK1) D10604 Binimetinib (JAN/USAN) <JP/US> MAP2K2 (MEK2) D10604 Binimetinib (JAN/USAN) <JP/US> New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D10604 New drug approvals in Europe [br08329.html] European public assessment reports (EPAR) authorised medicine D10604 New drug approvals in Japan [br08318.html] Drugs with new active ingredients D10604 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D10604 Pharmacogenomic biomarkers [br08341.html] Somatic variations in targeted cancer therapies D10604 | ||||||||
| Other DBs |
| ||||||||
| KCF data | ATOM 27 1 C8y C 12.9500 -16.7300 2 C8y C 12.9500 -18.1300 3 C8x C 14.1624 -18.8300 4 C8y C 15.3749 -18.1300 5 C8y C 15.3749 -16.7300 6 C8y C 14.1624 -16.0300 7 N4y N 16.7064 -18.5626 8 C8x C 17.5293 -17.4300 9 N5x N 16.7064 -16.2974 10 X F 14.1624 -14.6302 11 N1b N 11.7376 -16.0300 12 C5a C 11.7376 -18.8300 13 N1b N 10.5421 -18.1396 14 O5a O 11.7375 -20.2298 15 O2a O 9.3547 -18.8251 16 C1b C 8.1635 -18.1371 17 C1b C 6.9740 -18.8238 18 O1a O 5.7839 -18.1365 19 C8y C 11.7375 -14.6302 20 C8x C 12.9667 -13.9202 21 C8x C 12.9665 -12.5202 22 C8y C 11.7539 -11.8204 23 C8x C 10.5247 -12.5304 24 C8y C 10.5249 -13.9304 25 X Br 11.7538 -10.4300 26 X F 9.2942 -14.6414 27 C1a C 17.1375 -19.8894 BOND 29 1 1 2 2 2 2 3 1 3 3 4 2 4 4 5 1 5 5 6 2 6 1 6 1 7 4 7 1 8 7 8 1 9 8 9 2 10 5 9 1 11 6 10 1 12 1 11 1 13 2 12 1 14 12 13 1 15 12 14 2 16 13 15 1 17 15 16 1 18 16 17 1 19 17 18 1 20 11 19 1 21 19 20 2 22 20 21 1 23 21 22 2 24 22 23 1 25 23 24 2 26 19 24 1 27 22 25 1 28 24 26 1 29 7 27 1 |